Related Experiment Video For Canada
Updated: Mar 7, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Assessment of H-index and research impact amongst academic medical oncologists in Canada
Sera Whitelaw1, Daniel Jousé Guerra Ordaz2, Amina Moustaqim-Barrette2
1Department of Medicine, University of Toronto, Toronto, ON, Canada.
Introduction:
The h-index is widely used to measure academic productivity in medicine, yet data on research output among academic medical oncologists in Canada remain limited. This study aimed to characterize the academic profiles of Canadian medical oncologists and identify factors associated with higher h-index scores.
Methods:
A cross-sectional analysis of medical oncologists affiliated with Canadian universities was conducted using publicly available faculty listings, Scopus Author IDs, and professional certification records. Key demographic and academic variables-including sex, years since certification, academic rank, graduate degrees, region of practice, and Canadian Institutes of Health Research (CIHR) funding-were collected. Univariate and multivariate log-linear regression models were used to assess the relationship between these factors and the h-index.
Results:
A total of 391 medical oncologists were identified across 15 Canadian institutions. The median national h-index was 14.0, with regional and sex-based differences noted in descriptive statistics. However, in adjusted analyses, only higher academic rank and receipt of CIHR funding were significantly associated with increased h-index values. Other variables, including sex, graduate degrees, region, and years of practice, were not significant predictors of academic productivity.
Conclusion:
These findings highlight the role of institutional advancement and research funding in supporting academic output and may guide future research, policy development, and evaluation practices in academic oncology.
More Related Videos
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Survival Analysis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Comparing the Survival Analysis of Two or More Groups
Cancer

